It is well established that human cancer associated variants (mutations) of the TGF-β-BMP-SMAD4 pathway are correlated with poorer prognosis in enriched sub-types of intestinal cancers such colorectal and pancreatic adenocarcinoma2. This evidence concerns the gene SMAD4 and cancer.